Filtros de búsqueda

Lista de obras de Jeffrey Lieberman

A Longitudinal Study of Violent Behavior in a Psychosis-Risk Cohort

artículo científico publicado en 2017

A Multicenter, Rater-Blinded, Randomized Controlled Study of Auditory Processing-Focused Cognitive Remediation Combined With Open-Label Lurasidone in Patients With Schizophrenia and Schizoaffective Disorder

artículo científico

A Phase II study of a histamine H₃ receptor antagonist GSK239512 for cognitive impairment in stable schizophrenia subjects on antipsychotic therapy

artículo científico publicado en 2015

A Pilot Study of Risperidone, Olanzapine, and Haloperidol in Psychotic Youth: A Double-Blind, Randomized, 8-Week Trial ⬇️

artículo científico publicado el 1 de enero de 2004

A Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Tocilizumab, An Interleukin-6 Receptor Antibody, For Residual Symptoms in Schizophrenia

artículo científico publicado en 2017

A candidate gene study of Tardive dyskinesia in the CATIE schizophrenia trial

artículo científico publicado en 2010

A common polymorphism in the cannabinoid receptor 1 (CNR1) gene is associated with antipsychotic-induced weight gain in Schizophrenia

artículo científico publicado en 2010

A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls

artículo científico publicado en 2005

A contribution of novel CNVs to schizophrenia from a genome-wide study of 41,321 subjects

A historical review of placebo-controlled, relapse prevention trials in schizophrenia: The loss of clinical equipoise

artículo científico publicado en 2020

A hypothesis-driven association study of 28 nuclear-encoded mitochondrial genes with antipsychotic-induced weight gain in schizophrenia

artículo científico publicado en 2013

A multicenter study of ketamine effects on functional connectivity: Large scale network relationships, hubs and symptom mechanisms

A national study of violent behavior in persons with schizophrenia

artículo científico publicado en 2006

A predictive model for conversion to psychosis in clinical high-risk patients

artículo científico publicado en 2018

A randomized clinical trial of MK-0777 for the treatment of cognitive impairments in people with schizophrenia

artículo científico publicado en 2010

A randomized exploratory trial of an α-7 nicotinic receptor agonist (TC-5619) for cognitive enhancement in schizophrenia

artículo científico publicado en 2012

A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP)

scientific article published on 18 July 2011

A randomized, placebo-controlled study of memantine as adjunctive treatment in patients with schizophrenia

artículo científico publicado en 2008

A systematic method for estimating individual responses to treatment with antipsychotics in CATIE.

artículo científico publicado en 2008

AKT1 and neurocognition in schizophrenia.

artículo científico publicado en 2007

Adjunctive sapropterin dihydrochloride treatment in schizophrenia: A positive proof-of-concept, rater-blind, randomized, multivitamin-controlled study

scientific article published on 21 January 2020

Advancing drug discovery for schizophrenia

artículo científico publicado en 2011

Advancing study of cognitive impairments for antipsychotic-naïve psychosis comparing high-income versus low- and middle-income countries with a focus on urban China: Systematic review of cognition and study methodology

artículo científico publicado en 2020

Aggression and psychopathology in treatment-resistant inpatients with schizophrenia and schizoaffective disorder.

artículo científico publicado en 2005

Aggression and quantitative MRI measures of caudate in patients with chronic schizophrenia or schizoaffective disorder

artículo científico publicado en 2006

Alive but not well: the limited validity but continued utility of the concept of schizophrenia

artículo científico publicado en 2017

Alterations in regional brain metabolism in genetic and pharmacological models of reduced NMDA receptor function

artículo científico publicado en 2002

Amphetamine-induced Fos is reduced in limbic cortical regions but not in the caudate or accumbens in a genetic model of NMDA receptor hypofunction

scientific journal article

Amygdalar volume and violent ideation in a sample at clinical high-risk for psychosis

artículo científico publicado en 2019

An imaging-based risk calculator for prediction of conversion to psychosis in clinical high-risk individuals using glutamate 1H MRS

scientific article published on 12 September 2019

Anatomical abnormalities in gray and white matter of the cortical surface in persons with schizophrenia

artículo científico publicado en 2013

Anti-viral properties of antipsychotic medications in the time of COVID-19

artículo científico publicado en 2020

Antidepressant medications and other treatments of depressive disorders: a CINP Task Force report based on a review of evidence.

artículo científico publicado en 2007

Antipsychotic drug effects on brain morphology in first-episode psychosis

artículo científico publicado en 2005

Antipsychotic drugs for first-episode schizophrenia: a comparative review

artículo científico publicado en 2009

Antipsychotic drugs: comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection

artículo científico publicado en 2008

Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study

scientific article published on 04 September 2008

Antipsychotic-induced weight gain and therapeutic response: a differential association.

artículo científico publicado en 2002

Apoptotic mechanisms and the synaptic pathology of schizophrenia

artículo científico publicado en 2005

Apoptotic mechanisms in the pathophysiology of schizophrenia

artículo científico publicado en 2005

Apoptotic proteins in the temporal cortex in schizophrenia: high Bax/Bcl-2 ratio without caspase-3 activation

artículo científico publicado en 2004

Application of a single-objective, hybrid genetic algorithm approach to pharmacokinetic model building

artículo científico publicado en 2012

Are Placebo-Controlled, Relapse Prevention Trials in Schizophrenia Research Still Necessary or Ethical?

scientific article published on 01 July 2019

Aripiprazole versus haloperidol treatment in early-stage schizophrenia ⬇️

artículo científico publicado el 9 de octubre de 2010

Association Between the Duration of Untreated Psychosis and Selective Cognitive Performance in Community-Dwelling Individuals With Chronic Untreated Schizophrenia in Rural China

artículo científico publicado en 2020

Association Study of Serotonin 3 Receptor Subunit Gene Variants in Antipsychotic-Induced Weight Gain

artículo científico publicado en 2017

Association between the -2548G/A polymorphism of the leptin gene and antipsychotic-induced weight gain: Analysis of the CATIE sample and meta-analysis

scientific article published on 23 April 2020

Association of 9-Hydroxy Risperidone Concentrations With Risk of Switching or Discontinuation in the Clinical Antipsychotic Trial of Intervention Effectiveness-Alzheimer's Disease Trial ⬇️

artículo científico publicado el 1 de diciembre de 2010

Association of Allelic Variation in Genes Mediating Aspects of Energy Homeostasis with Weight Gain during Administration of Antipsychotic Drugs (CATIE Study).

artículo científico publicado en 2011

Association of RGS2 and RGS5 variants with schizophrenia symptom severity

artículo científico publicado en 2008

Association of a functional polymorphism in neuropeptide Y with antipsychotic-induced weight gain in schizophrenia patients.

artículo científico publicado en 2013

Association of orexin receptor polymorphisms with antipsychotic-induced weight gain

artículo científico publicado en 2015

Association of the alpha 2A adrenergic receptor -1291C/G polymorphism and antipsychotic-induced weight gain in European-Americans.

artículo científico publicado en 2009

Association of the orphan nuclear receptor NR4A1 with tardive dyskinesia

artículo científico publicado en 2010

Association study between a functional glutathione S-transferase (GSTP1) gene polymorphism (Ile105Val) and tardive dyskinesia

artículo científico publicado en 2005

Association study between the neurexin-1 gene and tardive dyskinesia

artículo científico publicado en 2017

Association study between variants of AMP-activated protein kinase catalytic and regulatory subunit genes with antipsychotic-induced weight gain

artículo científico publicado en 2012

Association study of 12 polymorphisms spanning the dopamine D(2) receptor gene and clozapine treatment response in two treatment refractory/intolerant populations

artículo científico publicado en 2005

Association study of BDNF and DRD3 genes in schizophrenia diagnosis using matched case-control and family based study designs.

artículo científico publicado en 2010

Association study of Disrupted-In-Schizophrenia-1 gene variants and tardive dyskinesia

scientific article published on 15 August 2018

Association study of GABAA α2 receptor subunit gene variants in antipsychotic-associated weight gain

artículo científico publicado en 2015

Association study of GRIK1 gene polymorphisms in schizophrenia: case-control and family-based studies

artículo científico publicado en 2012

Association study of GSK3 gene polymorphisms with schizophrenia and clozapine response

artículo científico publicado en 2008

Association study of four dopamine D1 receptor gene polymorphisms and clozapine treatment response

artículo científico publicado en 2006

Association study of polymorphisms in cholecystokinin gene and its receptors with antipsychotic induced weight gain in schizophrenia patients

artículo científico publicado en 2010

Association study of polymorphisms in insulin induced gene 2 (INSIG2) with antipsychotic-induced weight gain in European and African-American schizophrenia patients

artículo científico publicado en 2010

Association study of tardive dyskinesia and twelve DRD2 polymorphisms in schizophrenia patients

artículo científico publicado en 2006

Association study of the GSK-3B gene with tardive dyskinesia in European Caucasians

artículo científico publicado en 2010

Association study of the gamma-aminobutyric acid type a receptor gamma2 subunit gene with schizophrenia

artículo científico publicado en 2009

Association study of the vesicular monoamine transporter gene SLC18A2 with tardive dyskinesia

artículo científico publicado en 2013

Attentional modulation of early-stage visual processing in schizophrenia

artículo científico publicado en 2006

Atypical and Conventional Antipsychotic Drugs in Treatment-Naive First-Episode Schizophrenia: A 52-Week Randomized Trial of Clozapine Vs Chlorpromazine ⬇️

artículo científico publicado el 26 de marzo de 2003

Auditory P300 in high-risk, recent-onset and chronic schizophrenia

artículo científico publicado en 2005

Barriers to employment for people with schizophrenia

artículo científico publicado en 2006

Basal ganglia volumes in first-episode schizophrenia and healthy comparison subjects

artículo científico publicado en 2002

Baseline neurocognitive deficits in the CATIE schizophrenia trial.

artículo científico publicado en 2006

Brain volume in first-episode schizophrenia: systematic review and meta-analysis of magnetic resonance imaging studies

artículo científico publicado en 2006

Brain volumes in psychotic youth with schizophrenia and mood disorders

artículo científico publicado en 2010

C9ORF72 repeat expansions not detected in a group of patients with schizophrenia

artículo científico publicado en 2012

COMT158 polymorphism and hostility.

artículo científico publicado en 2004

Can a nonequivalent choice of dosing regimen bias the results of flexible dose double blind trials? The CATIE schizophrenia trial.

artículo científico publicado en 2009

Caspase-3 activation in rat frontal cortex following treatment with typical and atypical antipsychotics

artículo científico publicado en 2006

Catechol-O-Methyltransferase Val158Met Polymorphism and Clinical Response to Antipsychotic Treatment in Schizophrenia and Schizo-Affective Disorder Patients: a Meta-Analysis

artículo científico publicado en 2016

Catechol-O-methyltransferase and Monoamine Oxidase-A Polymorphisms and Treatment Response to Typical and Atypical Neuroleptics

article

Cerebrospinal fluid dehydroepiandrosterone levels are correlated with brain dehydroepiandrosterone levels, elevated in Alzheimer's disease, and related to neuropathological disease stage

artículo científico publicado en 2008

Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: prospective data from phase 1

artículo científico publicado en 2008

Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics

artículo científico publicado en 2003

Characterization of in vivo pharmacokinetic properties of the dopamine D1 receptor agonist DAR-0100A in nonhuman primates using PET with [11C] NNC112 and [11C] raclopride

artículo científico publicado en 2010

Cholinergic agonists as novel treatments for schizophrenia: the promise of rational drug development for psychiatry

artículo científico publicado en 2008

Chronic administration of haloperidol and olanzapine attenuates ketamine-induced brain metabolic activation

artículo científico publicado en 2003

Clinical correlates of tardive dyskinesia in schizophrenia: baseline data from the CATIE schizophrenia trial.

artículo científico publicado en 2005

Clinical symptom responses to atypical antipsychotic medications in Alzheimer's disease: phase 1 outcomes from the CATIE-AD effectiveness trial

artículo científico publicado en 2008

Clinical trials for antipsychotic drugs: design conventions, dilemmas and innovations.

artículo científico publicado en 2006

Clozapine as a first treatment for schizophrenia

artículo científico publicado en 2003

Clozapine markedly elevates pregnenolone in rat hippocampus, cerebral cortex, and serum: candidate mechanism for superior efficacy?

artículo científico publicado en 2006

Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder.

artículo científico publicado en 2002

Clozapine-induced agranulocytosis is associated with rare HLA-DQB1 and HLA-B alleles

artículo científico publicado en 2014

Clozapinev.chlorpromazine in treatment-naive, first-episode schizophrenia: 9-year outcomes of a randomised clinical trial ⬇️

artículo científico publicado el 1 de octubre de 2011

Cognitive development in schizophrenia: follow-back from the first episode.

artículo científico publicado en 2006

Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol

artículo científico publicado en 2004

Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol

artículo científico publicado en 2003

Comparing safety and tolerability of antipsychotic treatment.

artículo científico publicado en 2007

Comparison of antipsychotic medication effects on reducing violence in people with schizophrenia

artículo científico publicado en 2008

Comparison of quetiapine and risperidone in the treatment of schizophrenia: A randomized, double-blind, flexible-dose, 8-week study.

artículo científico publicado en 2006

Components and correlates of family burden in schizophrenia.

artículo científico publicado en 2006

Concurrent measurement of "real-world" stress and arousal in individuals with psychosis: assessing the feasibility and validity of a novel methodology

artículo científico publicado en 2009

Conflict of interest-- an issue for every psychiatrist

artículo científico publicado en 2009

Contribution of copy number variants to schizophrenia from a genome-wide study of 41,321 subjects

artículo científico publicado en 2016

Correction: Anatomical Abnormalities in Gray and White Matter of the Cortical Surface in Persons with Schizophrenia.

artículo científico publicado en 2013

Cost-effectiveness measures, methods, and policy implications from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for schizophrenia

artículo científico publicado en 2007

Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia

artículo científico publicado en 2006

Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol

artículo científico publicado en 2005

Cross-disorder genomewide analysis of schizophrenia, bipolar disorder, and depression

scientific journal article

Cross-sectional and longitudinal relationships between insight and attitudes toward medication and clinical outcomes in chronic schizophrenia

artículo científico publicado en 2008

Cumulative sojourn time in longitudinal studies: a sequential imputation method to handle missing health state data due to dropout

artículo científico publicado en 2014

Decision-making capacity for research participation among individuals in the CATIE schizophrenia trial.

artículo científico publicado en 2005

Deficits in sensorimotor gating and tests of social behavior in a genetic model of reduced NMDA receptor function

scientific journal article

Development and psychometric performance of the schizophrenia objective functioning instrument: an interviewer administered measure of function

artículo científico publicado en 2008

Developmental Effects of Prenatal Cocaine Exposure on 5-HT<sub>1A</sub> Receptors in Male and Female Rat Offspring ⬇️

artículo científico publicado el 1 de enero de 2002

Does switching to a new antipsychotic improve outcomes? Data from the CATIE Trial

artículo científico publicado en 2008

Dopamine D4 and D5 receptor gene variant effects on clozapine response in schizophrenia: replication and exploration

artículo científico publicado en 2011

Dopamine partial agonists: a new class of antipsychotic

artículo científico publicado en 2004

Double blind, two dose, randomized, placebo-controlled, cross-over clinical trial of the positive allosteric modulator at the alpha7 nicotinic cholinergic receptor AVL-3288 in schizophrenia patients

artículo científico publicado en 2020

Double-blind maintenance safety and effectiveness findings from the Treatment of Early-Onset Schizophrenia Spectrum (TEOSS) study

artículo científico publicado en 2010

Double-blind, placebo-controlled investigation of amantadine for weight loss in subjects who gained weight with olanzapine

artículo científico publicado en 2005

Dr Kantrowitz and Colleagues Reply

artículo científico publicado en 2016

Duration of untreated psychosis and time to treatment response for delusions and hallucinations

artículo científico publicado en 2005

Early Detection and Preventive Intervention in Schizophrenia: From Fantasy to Reality

artículo científico publicado en 2019

Early response to antipsychotic therapy as a clinical marker of subsequent response in the treatment of patients with first-episode psychosis.

artículo científico publicado en 2010

Effect of olanzapine on body composition and energy expenditure in adults with first-episode psychosis

artículo científico publicado en 2005

Effect of the neuroprotective peptide davunetide (AL-108) on cognition and functional capacity in schizophrenia

artículo científico publicado en 2011

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

artículo científico publicado en 2005

Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease.

artículo científico publicado en 2006

Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment

artículo científico publicado en 2006

Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study

artículo científico publicado en 2007

Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic

artículo científico publicado en 2006

Effectiveness of switching antipsychotic medications

artículo científico publicado en 2006

Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study.

artículo científico publicado en 2007

Effects of atypical antipsychotics on the syndromal profile in treatment-resistant schizophrenia

artículo científico publicado en 2004

Effects of davunetide on N-acetylaspartate and choline in dorsolateral prefrontal cortex in patients with schizophrenia

artículo científico publicado en 2013

Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison.

artículo científico publicado en 2007

Effects of risperidone on auditory event-related potentials in schizophrenia.

artículo científico publicado en 1999

Effects of the D1 Dopamine Receptor Agonist Dihydrexidine (DAR-0100A) on Working Memory in Schizotypal Personality Disorder

artículo científico publicado en 2014

Efficacy and Safety of Lumateperone for Treatment of Schizophrenia: A Randomized Clinical Trial

scientific article published on 08 January 2020

Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison

artículo científico publicado en 2007

Efficacy of clozapine, olanzapine, risperidone, and haloperidol in schizophrenia and schizoaffective disorder assessed with nurses observation scale for inpatient evaluation.

artículo científico publicado en 2004

Efficiency of the CATIE and BACS neuropsychological batteries in assessing cognitive effects of antipsychotic treatments in schizophrenia

artículo científico publicado en 2008

Electrophysiological indices of automatic and controlled auditory information processing in first-episode, recent-onset and chronic schizophrenia

artículo científico publicado en 2006

Eliminating the Glass Ceiling in Academic Psychiatry

artículo científico publicado en 2017

Ellen Stover

artículo científico publicado en 2014

Employment outcomes in a randomized trial of second-generation antipsychotics and perphenazine in the treatment of individuals with schizophrenia.

artículo científico publicado en 2008

Ethnic stratification of the association of RGS4 variants with antipsychotic treatment response in schizophrenia.

artículo científico publicado en 2007

Exploratory study on association of genetic variation in TBC1D1 with antipsychotic-induced weight gain

artículo científico publicado en 2013

Extrapyramidal side-effects of antipsychotics in a randomised trial

artículo científico publicado en 2008

F1. GENOME-WIDE ASSOCIATION STUDIES SUGGESTED ASSOCIATION BETWEEN DGKB AND ANTIPSYCHOTIC INDUCED WEIGHT GAIN IN EUROPEANS AND AFRICAN AMERICANS.

artículo científico publicado en 2018

Facial emotion perception and fusiform gyrus volume in first episode schizophrenia

artículo científico publicado en 2005

Family and case-control association study of the tumor necrosis factor-alpha (TNF-alpha) gene with schizophrenia and response to antipsychotic medication.

artículo científico publicado en 2006

Fat mass- and obesity-associated (FTO) gene and antipsychotic-induced weight gain: an association study

artículo científico publicado en 2014

Finite mixture regression model analysis on antipsychotics induced weight gain: investigation of the role of the serotonergic genes

artículo científico publicado en 2012

First episode schizophrenia-related psychosis and substance use disorders: acute response to olanzapine and haloperidol

artículo científico publicado en 2004

From Clinical Research to Clinical Practice: A 4-Year Review of Ziprasidone

From clinical research to clinical practice: a 4-year review of ziprasidone

artículo científico publicado en 2005

Gene-gene interaction analyses between NMDA receptor subunit and dopamine receptor gene variants and clozapine response.

artículo científico publicado en 2011

Genetic association analysis of N-methyl-D-aspartate receptor subunit gene GRIN2B and clinical response to clozapine

artículo científico publicado en 2016

Genetic association of the GDNF alpha-receptor genes with schizophrenia and clozapine response.

artículo científico publicado en 2010

Genetic interactions in the adrenergic system genes: analysis of antipsychotic-induced weight gain

artículo científico publicado en 2011

Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs

artículo científico publicado en 2013

Genetic study of BDNF, DRD3, and their interaction in tardive dyskinesia

artículo científico publicado en 2009

Genetic study of eight AKT1 gene polymorphisms and their interaction with DRD2 gene polymorphisms in tardive dyskinesia

artículo científico publicado en 2008

Genetic study of neuregulin 1 and receptor tyrosine-protein kinase erbB-4 in tardive dyskinesia

artículo científico publicado en 2017

Genetic variation in the GCG and in the GLP1R genes and antipsychotic-induced weight gain

artículo científico publicado en 2014

Genome-wide association study on antipsychotic-induced weight gain in Europeans and African-Americans

artículo científico publicado en 2019

Genome-wide pharmacogenomic study of neurocognition as an indicator of antipsychotic treatment response in schizophrenia.

artículo científico publicado en 2010

Genomewide association study of movement-related adverse antipsychotic effects

artículo científico publicado en 2009

Genomic dissection of bipolar disorder and schizophrenia including 28 subphenotypes

artículo científico publicado en 2017

Glial cell line-derived neurotrophic factor receptor alpha 2 (GFRA2) gene is associated with tardive dyskinesia.

artículo científico publicado en 2010

Glutamatergic abnormalities in schizophrenia: a review of proton MRS findings

artículo científico publicado en 2014

Grant Report on d-Serine Augmentation of Neuroplasticity-Based Auditory Learning in Schizophrenia †

artículo científico publicado en 2020

Guest editors' introduction: what can large pragmatic clinical trials do for public mental health care?

artículo científico publicado en 2003

HTR2C haplotypes and antipsychotics-induced weight gain: X-linked multimarker analysis

artículo científico publicado en 2007

Hippocampal Pathology in Clinical High-Risk Patients and the Onset of Schizophrenia

scientific article published on 03 October 2019

Hippocampal shape and volume changes with antipsychotics in early stage psychotic illness

artículo científico publicado en 2012

How mental health care should change as a consequence of the COVID-19 pandemic

artículo científico publicado en 2020

ITI-007 for the Treatment of Schizophrenia: A 4-Week Randomized, Double-Blind, Controlled Trial.

artículo científico publicado en 2015

Identification of a naturally occurring 21 bp deletion in alpha 2c noradrenergic receptor gene and cognitive correlates to antipsychotic treatment.

artículo científico publicado en 2005

Identifying clinically questionable psychotropic prescribing practices for medicaid recipients in new york state.

artículo científico publicado en 2009

Impact of antipsychotic medication on family burden in schizophrenia: longitudinal results of CATIE trial

artículo científico publicado en 2009

Impact of antipsychotic treatment on nonfasting triglycerides in the CATIE Schizophrenia Trial phase 1.

artículo científico publicado en 2008

Impact of histamine receptors H1 and H3 polymorphisms on antipsychotic-induced weight gain

artículo científico publicado en 2016

Impact of second-generation antipsychotics and perphenazine on depressive symptoms in a randomized trial of treatment for chronic schizophrenia

scientific article published on 21 September 2010

Impairments in perceptual competency and maintenance on a visual delayed match-to-sample test in first-episode schizophrenia

artículo científico publicado en 2003

Implications for the Neural Basis of Social Cognition for the Study of Schizophrenia

artículo científico publicado el 1 de mayo de 2003

Improving classification of psychoses

artículo científico publicado en 2016

In search of moderators and mediators of hyperglycemia with atypical antipsychotic treatment

artículo científico publicado en 2009

Inflammatory markers in schizophrenia: comparing antipsychotic effects in phase 1 of the clinical antipsychotic trials of intervention effectiveness study.

artículo científico publicado en 2009

Influence of neurexin 1 (NRXN1) polymorphisms in clozapine response.

artículo científico publicado en 2010

Influence of serotonin 3A and 3B receptor genes on clozapine treatment response in schizophrenia

artículo científico publicado en 2010

Insight in first-episode psychosis

artículo científico publicado en 2006

Interaction Testing and Polygenic Risk Scoring to Estimate the Association of Common Genetic Variants With Treatment Resistance in Schizophrenia

artículo científico publicado en 2022

Interpreting the results of the CATIE study

scientific article published on 01 January 2006

Interrelationships of psychiatric symptom severity, medical comorbidity, and functioning in schizophrenia

artículo científico publicado en 2006

Intrinsic Regression Models for Manifold-Valued Data

artículo científico publicado en 2009

Intrinsic regression models for manifold-valued data

artículo científico publicado en 2009

Investigation of TSPO variants in schizophrenia and antipsychotic treatment outcomes

artículo científico publicado en 2015

Investigation of melanocortin system gene variants in antipsychotic-induced weight gain

artículo científico publicado en 2014

Investigation of the Gene in Tardive Dyskinesia - New Data and Meta-Analysis

article

It is time to take a stand for medical research and against terrorism targeting medical scientists

artículo científico publicado en 2008

Lack of association between HTR4 gene polymorphisms and schizophrenia in case-control and family-based samples

artículo científico publicado en 2009

Lack of association of GPX1 and MnSOD genes with symptom severity and response to clozapine treatment in schizophrenia subjects

artículo científico publicado en 2009

Lack of association of NALCN genetic variants with schizophrenia.

artículo científico publicado en 2010

Lack of normal association between cerebellar volume and neuropsychological functions in first-episode schizophrenia.

artículo científico publicado en 2003

Liver enzyme CYP2D6 gene and tardive dyskinesia

scientific article published on 24 September 2020

Localized differences in caudate and hippocampal shape are associated with schizophrenia but not antipsychotic type

artículo científico publicado en 2012

Long-term neurocognitive effects of olanzapine or low-dose haloperidol in first-episode psychosis

artículo científico publicado en 2005

Longitudinal consent-related abilities among research participants with schizophrenia: results from the CATIE study.

artículo científico publicado en 2011

Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline

artículo científico publicado en 2006

MDR1 gene in tardive dyskinesia scale scores: comparison of strategies for quantitative trait haplotype analysis.

artículo científico publicado en 2009

Mapping genomic loci implicates genes and synaptic biology in schizophrenia

artículo científico publicado en 2022

Measurement of brain metabolites by 1H magnetic resonance spectroscopy in patients with schizophrenia: a systematic review and meta-analysis

artículo científico publicado en 2005

Measuring outcome priorities and preferences in people with schizophrenia.

artículo científico publicado en 2005

Metabolic profiles of second-generation antipsychotics in early psychosis: findings from the CAFE study.

artículo científico publicado en 2009

Metformin for weight loss and metabolic control in overweight outpatients with schizophrenia and schizoaffective disorder

artículo científico publicado en 2013

Microduplications of 16p11.2 are associated with schizophrenia

artículo científico publicado en 2009

Molecular pathophysiology of metabolic effects of antipsychotic medications

artículo científico

Myocarditis during clozapine treatment

artículo científico publicado en 2006

NCAM1 and neurocognition in schizophrenia

artículo científico publicado en 2006

Neonatal neurosteroid administration alters parvalbumin expression and neuron number in medial dorsal thalamus of adult rats

artículo científico publicado en 2004

Neonatal neurosteroid administration results in development-specific alterations in prepulse inhibition and locomotor activity: neurosteroids alter prepulse inhibition and locomotor activity

artículo científico

Neural correlates of automatic and controlled auditory processing in schizophrenia

artículo científico publicado en 2008

Neuroactive Steroids are Altered in Schizophrenia and Bipolar Disorder: Relevance to Pathophysiology and Therapeutics

artículo científico publicado en 2005

Neurocognition in early-onset schizophrenia and schizoaffective disorders

artículo científico publicado en 2010

Neurocognitive correlates of response to treatment in formal thought disorder in patients with first-episode schizophrenia

artículo científico

Neurocognitive correlates of the COMT Val(158)Met polymorphism in chronic schizophrenia.

artículo científico publicado en 2002

Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial

artículo científico publicado en 2007

Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder

artículo científico publicado en 2002

Neurocognitive outcomes in the Treatment of Early-Onset Schizophrenia Spectrum Disorders study

artículo científico publicado en 2012

Neuroprotection in schizophrenia

artículo científico publicado en 2006

Neuroprotection: a therapeutic strategy to prevent deterioration associated with schizophrenia.

artículo científico publicado en 2007

Neuropsychological correlates of hippocampal volumes in patients experiencing a first episode of schizophrenia.

artículo científico publicado en 2002

New data and an old puzzle: the negative association between schizophrenia and rheumatoid arthritis

artículo científico publicado en 2015

New insights into tardive dyskinesia genetics: Implementation of whole-exome sequencing approach

artículo científico publicado en 2019

No association of the serotonin transporter polymorphisms 5-HTTLPR and RS25531 with schizophrenia or neurocognition.

artículo científico publicado en 2010

No evidence for a role of the peroxisome proliferator-activated receptor gamma (PPARG) and adiponectin (ADIPOQ) genes in antipsychotic-induced weight gain

artículo científico publicado en 2014

Olanzapine and clozapine increase the GABAergic neuroactive steroid allopregnanolone in rodents

artículo científico publicado en 2003

Olanzapine and fluoxetine administration and coadministration increase rat hippocampal pregnenolone, allopregnanolone and peripheral deoxycorticosterone: implications for therapeutic actions

artículo científico publicado en 2006

Olanzapine in refractory schizophrenia after failure of typical or atypical antipsychotic treatment: an open-label switch study

artículo científico publicado en 2002

Olanzapine versus risperidone in newly admitted acutely ill psychotic patients

artículo científico publicado en 2005

Overt aggression and psychotic symptoms in patients with schizophrenia treated with clozapine, olanzapine, risperidone, or haloperidol

artículo científico publicado en 2004

Oxidative stress in tardive dyskinesia: genetic association study and meta-analysis of NADPH quinine oxidoreductase 1 (NQO1) and Superoxide dismutase 2 (SOD2, MnSOD) genes

artículo científico publicado en 2009

Oxytocin, dopamine, and the amygdala: a neurofunctional model of social cognitive deficits in schizophrenia

artículo científico publicado en 2010

PM389. Preliminary Genetic Model Predicting Clozapine Response.

artículo científico publicado en 2016

Pathophysiology of drug induced weight and metabolic effects: findings from an RCT in healthy volunteers treated with olanzapine, iloperidone, or placebo.

artículo científico publicado en 2018

Perinatal flunitrazepam exposure causes persistent alteration of parvalbumin-immunoreactive interneuron localization in rat prefrontal cortex

artículo científico publicado en 2004

Pharmacogenetic Analysis of Functional Glutamate System Gene Variants and Clinical Response to Clozapine

artículo científico publicado en 2016

Pharmacological management of first-episode schizophrenia and related nonaffective psychoses

artículo científico publicado en 2003

Phosphodiesterase 4B genetic variants are not associated with antipsychotic-induced tardive dyskinesia

artículo científico publicado en 2010

Physical health monitoring of patients with schizophrenia

artículo científico publicado en 2004

Placebo response in antipsychotic clinical trials: a meta-analysis

artículo científico publicado en 2014

Polymorphisms of the HTR2C gene and antipsychotic-induced weight gain: an update and meta-analysis

artículo científico publicado en 2010

Population pharmacokinetic modeling of ziprasidone in patients with schizophrenia from the CATIE study

artículo científico publicado en 2011

Population pharmacokinetics of perphenazine in schizophrenia patients from CATIE: impact of race and smoking

artículo científico publicado en 2009

Predictors of antipsychotic medication adherence in patients recovering from a first psychotic episode

artículo científico publicado en 2006

Predictors of antipsychotic treatment response in patients with first-episode schizophrenia, schizoaffective and schizophreniform disorders

artículo científico publicado en 2004

Predictors of medication discontinuation by patients with first-episode schizophrenia and schizoaffective disorder.

artículo científico publicado en 2002

Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: a randomized, double-blind, flexible-dose, multicenter study.

artículo científico

Preliminary evidence for association of genome-wide significant DRD2 schizophrenia risk variant with clozapine response

artículo científico publicado en 2015

Premorbid functioning in schizophrenia: relation to baseline symptoms, treatment response, and medication side effects

artículo científico publicado en 2004

Prenatal and neonatal brain structure and white matter maturation in children at high risk for schizophrenia

artículo científico publicado en 2010

Prevalence and phenomenology of violent ideation and behavior among 200 young people at clinical high-risk for psychosis: an emerging model of violence and psychotic illness

artículo científico publicado en 2018

Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III.

artículo científico publicado en 2005

Preventing clinical deterioration in the course of schizophrenia: the potential for neuroprotection.

artículo científico publicado en 2006

Preventing clinical deterioration in the course of schizophrenia: the potential for neuroprotection.

artículo científico publicado en 2006

Pro-apoptotic Par-4 and dopamine D2 receptor in temporal cortex in schizophrenia, bipolar disorder and major depression

artículo científico publicado en 2010

Prolactin as a biomarker for treatment response and tardive dyskinesia in schizophrenia subjects: old thoughts revisited from a genetic perspective.

artículo científico publicado en 2011

Prolactin levels in schizophrenia and schizoaffective disorder patients treated with clozapine, olanzapine, risperidone, or haloperidol.

artículo científico publicado en 2004

Proof of mechanism and target engagement of glutamatergic drugs for the treatment of schizophrenia: RCTs of pomaglumetad and TS-134 on ketamine-induced psychotic symptoms and pharmacoBOLD in healthy volunteers

scientific article published on 13 May 2020

Proof-of-concept trial with the neurosteroid pregnenolone targeting cognitive and negative symptoms in schizophrenia

artículo científico publicado en 2009

Protein kinase cAMP-dependent regulatory type II beta (PRKAR2B) gene variants in antipsychotic-induced weight gain.

artículo científico publicado en 2014

Psychosocial treatment for first-episode psychosis: a research update

artículo científico publicado en 2005

Psychotic Disorders

artículo científico publicado en 2018

Quality of life during treatment with haloperidol or olanzapine in the year following a first psychotic episode

artículo científico publicado en 2005

Quantitative MRI measures of orbitofrontal cortex in patients with chronic schizophrenia or schizoaffective disorder

artículo científico publicado en 2005

Raising the standard of care for schizophrenia is an achievable goal

scientific article published on 04 April 2017

Recent advances in the development of novel pharmacological agents for the treatment of cognitive impairments in schizophrenia

artículo científico publicado en 2007

Recent advances in the neurobiology of schizophrenia

artículo científico publicado en 2003

Regional gray matter growth, sexual dimorphism, and cerebral asymmetry in the neonatal brain

artículo científico publicado en 2007

Relationship between duration of untreated psychosis and outcome in first-episode schizophrenia: a critical review and meta-analysis

artículo científico publicado en 2005

Relationship of cognition and psychopathology to functional impairment in schizophrenia

artículo científico publicado en 2008

Results of phase 3 of the CATIE schizophrenia trial

artículo científico publicado en 2008

Reversed cerebellar asymmetry in men with first-episode schizophrenia

artículo científico publicado en 2003

Revised PORT recommendations.

artículo científico publicado en 2004

Role of ethnicity in antipsychotic-induced weight gain and tardive dyskinesia: genes or environment?

artículo científico publicado en 2013

SU3. Preliminary Study for Association of Genome-Wide Significant Glutamate Receptor Schizophrenia Risk Variants With Clozapine Response.

artículo científico publicado en 2017

Schizophrenia severity and clozapine treatment outcome association with oxytocinergic genes

artículo científico publicado en 2010

Schizophrenia, VI: Treatments ⬇️

artículo científico publicado el 1 de octubre de 2003

Schizophrenia-associated gene dysbindin-1 and tardive dyskinesia

scientific article published on 11 May 2020

Schizophrenia: new pathological insights and therapies

artículo científico publicado en 2007

Science and recovery in schizophrenia

artículo científico publicado en 2008

Second-generation antipsychotics: reviewing the cost-effectiveness component of the CATIE trial

artículo científico publicado en 2007

Secretin for refractory schizophrenia.

artículo científico publicado en 2004

Secretin in a patient with treatment-resistant schizophrenia and prominent autistic features.

artículo científico publicado en 2004

Signaling pathways in schizophrenia: emerging targets and therapeutic strategies

artículo científico publicado en 2010

Single-voxel 1H PRESS at 4.0 T: precision and variability of measurements in anterior cingulate and hippocampus.

artículo científico publicado en 2006

Standard and higher dose of olanzapine in patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, fixed-dose study

artículo científico publicado en 2008

Striatal volume changes in the rat following long-term administration of typical and atypical antipsychotic drugs.

artículo científico publicado en 2002

Substance use and psychosocial functioning in schizophrenia among new enrollees in the NIMH CATIE study.

artículo científico publicado en 2006

Substance use in persons with schizophrenia: baseline prevalence and correlates from the NIMH CATIE study

artículo científico publicado en 2006

Successful rechallenge with clozapine after eosinophilia

scientific article published on 01 November 2011

Suggestive association between the C825T polymorphism of the G-protein beta3 subunit gene (GNB3) and clinical improvement with antipsychotics in schizophrenia

artículo científico publicado en 2005

T7. PHARMACOGENETIC OF TARDIVE DYSKINESIA -- A FOLLOW-UP ON THE VALBENAZINE TARGET VMAT2/SLC18A2.

artículo científico publicado en 2018

Teaching trainees to negotiate research collaborations with industry: a mentorship model

artículo científico publicado en 2010

The AmpliChip® CYP450 test and response to treatment in schizophrenia and obsessive compulsive disorder: a pilot study and focus on cases with abnormal CYP2D6 drug metabolism

artículo científico publicado en 2012

The Clinical Antipsychotic Trials Of Intervention Effectiveness (CATIE) Schizophrenia Trial: clinical comparison of subgroups with and without the metabolic syndrome.

artículo científico publicado en 2005

The Long-Term Effects of Antipsychotic Medication on Clinical Course in Schizophrenia

artículo científico publicado en 2017

The Mount Sinai conference on the pharmacotherapy of schizophrenia

artículo científico publicado en 2002

The NIMH-CATIE Schizophrenia Study: what did we learn?

artículo científico publicado en 2011

The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development

artículo científico publicado en 2003

The SNAP-25 gene may be associated with clinical response and weight gain in antipsychotic treatment of schizophrenia

artículo científico publicado en 2005

The association between weight change and symptom reduction in the CATIE schizophrenia trial ⬇️

artículo científico publicado el 21 de febrero de 2011

The catechol-O-methyl-transferase gene in tardive dyskinesia

artículo científico publicado en 2010

The characteristics of cognitive neuroscience tests in a schizophrenia cognition clinical trial: Psychometric properties and correlations with standard measures

scientific article published on 31 October 2019

The effectiveness of antipsychotic medications in patients who use or avoid illicit substances: results from the CATIE study.

artículo científico publicado en 2008

The effects of antipsychotic medications on emotion perception in patients with chronic schizophrenia in the CATIE trial

artículo científico publicado en 2009

The impact of obesity on health care costs among persons with schizophrenia

scientific article published on 23 October 2008

The moral imperatives of medical research in human subjects

artículo científico publicado en 1994

The neuregulin 1 promoter polymorphism rs6994992 is not associated with chronic schizophrenia or neurocognition.

artículo científico publicado en 2008

The neurosteroid allopregnanolone is reduced in prefrontal cortex in Alzheimer's disease

artículo científico publicado en 2006

The past and future of novel, non-dopamine-2 receptor therapeutics for schizophrenia: A critical and comprehensive review

article

The putative functional rs1045881 marker of neurexin-1 in schizophrenia and clozapine response

artículo científico publicado en 2011

The role of brain-derived neurotrophic factor (BDNF) gene variants in antipsychotic response and antipsychotic-induced weight gain

artículo científico publicado en 2012

The role of genetic variation across IL-1β, IL-2, IL-6, and BDNF in antipsychotic-induced weight gain

artículo científico publicado en 2015

Time to All-cause Treatment Discontinuation as the Primary Outcome in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Schizophrenia Study

artículo científico publicado en 2011

Time-lapse mapping of cortical changes in schizophrenia with different treatments

article

Towards diagnostic markers for the psychoses

artículo científico publicado en 2016

Treatment of early-onset schizophrenia spectrum disorders (TEOSS): demographic and clinical characteristics

artículo científico publicado en 2007

Treatment of early-onset schizophrenia spectrum disorders (TEOSS): rationale, design, and methods

artículo científico publicado en 2007

Treatment outcomes of patients with tardive dyskinesia and chronic schizophrenia.

artículo científico publicado en 2010

Use of Antipsychotics Pre- and Post-Dissemination of CATIE Data ⬇️

artículo científico publicado el 1 de mayo de 2007

Utility of Imaging-Based Biomarkers for Glutamate-Targeted Drug Development in Psychotic Disorders: A Randomized Clinical Trial

artículo científico publicado en 2017

What CATIE found: results from the schizophrenia trial

artículo científico publicado en 2008

What the CATIE study means for clinical practice

artículo científico publicado en 2006

World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance

artículo científico publicado en 2012

World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia. Part 3: Update 2015 Management of special circumstances: Depression, Suicidality, substance use disorders and pregnancy and lactatio

artículo científico

World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia - a short version for primary care

artículo científico publicado en 2017

World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, Part 1: acute treatment of schizophrenia

artículo científico publicado en 2005

World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: long-term treatment of schizophrenia

artículo científico publicado en 2006

World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects

artículo científico publicado en 2012

Ziprasidone alternative for olanzapine-induced hyperglycemia

artículo científico publicado en 2002

Dominio Público Uruguay está sostenido por:

Acerca de Dominio Público Uruguay

Ayuda